Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2025-09-02 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物股票交易异常波动公告.doc
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the board of directors of Maiwei (Shanghai) Biotech Co., Ltd. regarding abnormal stock price fluctuations over three consecutive trading days. It includes details about the company's self-investigation, confirmation of no undisclosed material information, risk warnings to investors, and compliance with disclosure regulations. The document does not contain financial statements, detailed financial analysis, or comprehensive report content. It is a regulatory announcement addressing stock price volatility and related disclosures, typical of a Regulatory Filing (RNS). The document length is short (1924 characters), and it is not a report itself but an announcement about stock trading conditions and company statements. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-09-02 Chinese
迈威生物关于以集中竞价交易方式回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about the progress of its share repurchase (buyback) plan. It details the board resolutions approving the buyback, the intended use of repurchased shares (employee stock plans or equity incentives), the price limits, and the current status of the buyback (no shares repurchased yet). It references regulatory rules on share repurchases and states the company will disclose progress monthly. The document is not a financial report, earnings release, or management discussion, but a formal update on the company's share repurchase activity. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares. The document length is short and focused solely on the buyback progress, not a broader financial or strategic report.
2025-08-31 Chinese
迈威生物关于重新向香港联交所递交H股发行并上市的申请并刊发申请资料的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Maiwei (Shanghai) Biotech Co., Ltd. regarding the resubmission of an application to the Hong Kong Stock Exchange for an H-share issuance and listing. It includes disclaimers about the application materials, links to the application documents on the HKEX website, and notes that the application is subject to regulatory approvals. The document is short (1050 characters) and primarily serves to inform investors about the filing and provide access to the application materials rather than containing the full application or financial data itself. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain detailed financial reports or results. It is not a full capital/financing update (CAP) because it does not detail the financing terms or results, but rather announces the filing and provides links to the documents. Therefore, the best classification is Regulatory Filings (RNS).
2025-08-31 Chinese
迈威生物自愿披露关于9MW3811注射液临床试验申请获得国家药品监督管理局受理的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Maiwei (Shanghai) Biotech Co., Ltd. regarding the acceptance of a clinical trial application for the drug 9MW3811 by the National Medical Products Administration (NMPA). It includes details about the drug, clinical trial status, licensing agreements, and risk warnings. The document is relatively short (2151 characters) and serves as an official announcement of regulatory acceptance rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report publication announcement since it contains substantive information about the clinical trial acceptance and related business updates. The document fits best under Regulatory Filings (RNS) as a general regulatory announcement about clinical trial acceptance and related corporate disclosures that do not fit other specific categories.
2025-08-31 Chinese
迈威生物自愿披露关于地舒单抗注射液获得巴基斯坦上市许可的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of the approval of a pharmaceutical product (地舒单抗注射液) for market registration in Pakistan. It details the product information, regulatory approval, market potential, and cooperation agreements. There are no financial statements, earnings data, or detailed financial analysis. The document is an official announcement about a regulatory approval and business development milestone, not a financial report or detailed investor presentation. It is not a report publication announcement since it contains substantive content rather than just a notice of report availability. Therefore, the document fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2025-08-31 Chinese
迈威生物关于公司2025年度“提质增效重回报”行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025年度"提质增效重回报"行动方案 半年度评估报告' which translates to a '2025 Annual "Quality Improvement and Efficiency Return" Action Plan Half-Year Assessment Report'. It contains detailed operational, R&D, commercial, governance, and financial progress information for the first half of 2025. The content includes financial figures, business strategy, R&D pipeline updates, governance improvements, and investor relations activities. The document is comprehensive and covers a period shorter than a full fiscal year (half-year). It is not merely an announcement or a brief summary but a substantive report with financial and operational data. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-08-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.